FierceBiotech

For the Treatment of Asthma, Surveyed Physicians’ Prescribing Practices of LABA/ICS Fixed-Dose Combinations (FDCs) Show that Competition is Tight Between GlaxoSmithKline’s ...

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of asthma, surveyed physicians’ prescribing practices ...
Nature

Inappropriate prescribing of combination inhalers in Northern Ireland: retrospective cross-sectional cohort study of prescribing practice in primary care

Asthma management guidelines advocate a stepwise approach to asthma therapy, including the addition of a long-acting bronchodilator to inhaled steroid therapy at step 3. This is almost exclusively ...
Business Wire

GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily ...
FierceBiotech

GlaxoSmithKline statement on FDA Advisory Committee vote on use of asthma medicines containing long-acting beta-agonists

Washington, DC - December 11, 2008 - The following is GlaxoSmithKline's [NYSE: GSK] statement regarding recommendations of a combined Advisory Committee to the FDA on the use of asthma medicines ...
FiercePharma

NEJM publishes results of GSK's long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced publication of results from the 'LABA' (long acting beta2-agonist) safety study, AUSTRI (SAS115359) in the New England Journal of Medicine (NEJM).
FiercePharma

GSK's Advair ® Diskus® achieves primary endpoint in LABA safety study of patients with asthma

GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
London South East

FDA approval - on ICS/LABA combinations in asthma

FDA approval - on ICS/LABA combinations in asthma | Regulatory News The AUSTRI study is a global, multicentre, randomised stratified, double-blind, parallel-group active comparator, 26 week study in ...
Pharmabiz

GSK announces Advair Diskus achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma

GlaxoSmithKline plc (GSK) announced results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study. VESTRI (SAS115358) compared Advair Diskus (FSC), a combination of the LABA, salmeterol, ...